JP2023506779A5 - - Google Patents
Info
- Publication number
- JP2023506779A5 JP2023506779A5 JP2022535607A JP2022535607A JP2023506779A5 JP 2023506779 A5 JP2023506779 A5 JP 2023506779A5 JP 2022535607 A JP2022535607 A JP 2022535607A JP 2022535607 A JP2022535607 A JP 2022535607A JP 2023506779 A5 JP2023506779 A5 JP 2023506779A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- pharmaceutical composition
- antibody
- composition according
- versus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945842P | 2019-12-09 | 2019-12-09 | |
| US62/945,842 | 2019-12-09 | ||
| US202063110111P | 2020-11-05 | 2020-11-05 | |
| US63/110,111 | 2020-11-05 | ||
| PCT/US2020/064010 WO2021119128A1 (en) | 2019-12-09 | 2020-12-09 | Antibodies for the treatment of chronic graft versus host disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506779A JP2023506779A (ja) | 2023-02-20 |
| JP2023506779A5 true JP2023506779A5 (https=) | 2023-12-13 |
Family
ID=76330540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535607A Pending JP2023506779A (ja) | 2019-12-09 | 2020-12-09 | 慢性移植片対宿主病の処置用抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12552869B2 (https=) |
| EP (1) | EP4073100A4 (https=) |
| JP (1) | JP2023506779A (https=) |
| KR (1) | KR20220123004A (https=) |
| CN (1) | CN115298210A (https=) |
| AU (1) | AU2020401551A1 (https=) |
| CA (1) | CA3164126A1 (https=) |
| IL (1) | IL293705A (https=) |
| MX (1) | MX2022007029A (https=) |
| PH (1) | PH12022551401A1 (https=) |
| WO (1) | WO2021119128A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260013464A (ko) * | 2023-05-17 | 2026-01-28 | 신닥스 파마슈티컬스, 인크. | 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법 |
| CN121620392A (zh) * | 2023-07-23 | 2026-03-06 | 因赛特公司 | 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| JP2008526773A (ja) * | 2004-12-30 | 2008-07-24 | ドール バイオファーマ、インコーポレイテッド | ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療 |
| WO2007142667A2 (en) | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| EP2076266A2 (en) | 2006-05-31 | 2009-07-08 | The Board of Trustees of the Leland Stanford Junior University | Method of treating inflammatory diseases using tyroskine kinase inhibitors |
| WO2008055013A2 (en) | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US20090148905A1 (en) | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| BRPI0909044B8 (pt) | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
| WO2010012667A1 (en) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Micro-rna mediated modulation of colony stimulating factors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| ES2763309T3 (es) | 2015-02-09 | 2020-05-28 | UCB Biopharma SRL | Formulación farmacéutica que comprende anticuerpos |
| CN111278459A (zh) * | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
-
2020
- 2020-12-09 EP EP20899869.0A patent/EP4073100A4/en active Pending
- 2020-12-09 CA CA3164126A patent/CA3164126A1/en active Pending
- 2020-12-09 KR KR1020227023446A patent/KR20220123004A/ko active Pending
- 2020-12-09 CN CN202080095646.6A patent/CN115298210A/zh active Pending
- 2020-12-09 US US17/783,552 patent/US12552869B2/en active Active
- 2020-12-09 AU AU2020401551A patent/AU2020401551A1/en active Pending
- 2020-12-09 PH PH1/2022/551401A patent/PH12022551401A1/en unknown
- 2020-12-09 MX MX2022007029A patent/MX2022007029A/es unknown
- 2020-12-09 JP JP2022535607A patent/JP2023506779A/ja active Pending
- 2020-12-09 WO PCT/US2020/064010 patent/WO2021119128A1/en not_active Ceased
- 2020-12-09 IL IL293705A patent/IL293705A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016606A5 (https=) | ||
| JP2023517236A5 (https=) | ||
| JP2019523295A5 (https=) | ||
| JP2010520290A5 (https=) | ||
| JP2011506483A5 (https=) | ||
| JP2020525411A5 (https=) | ||
| CA2984464C (en) | Treatment for multiple myeloma (mm) | |
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| IL319803A (en) | Methods and compositions for treating amyloid deposition diseases | |
| JP2018522540A5 (https=) | ||
| JP2024534602A5 (https=) | ||
| JP2013521252A5 (https=) | ||
| WO2013140787A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| JP2023520771A5 (https=) | ||
| JP2024540226A5 (https=) | ||
| JP2022542472A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| JP2022536088A5 (https=) | ||
| JP2021523138A5 (https=) | ||
| JP2023537078A5 (https=) | ||
| CN114729054A (zh) | 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 | |
| JP2022512346A5 (https=) | ||
| JP2024540435A5 (https=) | ||
| JP2021529766A5 (https=) | ||
| JP2024528877A5 (https=) |